Published in J Immunol on September 01, 2007
Isotype modulates epitope specificity, affinity, and antiviral activities of anti-HIV-1 human broadly neutralizing 2F5 antibody. Proc Natl Acad Sci U S A (2012) 1.50
Multi-faceted functions of secretory IgA at mucosal surfaces. Front Immunol (2013) 1.19
HIV-specific functional antibody responses in breast milk mirror those in plasma and are primarily mediated by IgG antibodies. J Virol (2011) 1.15
Mucosal immunity and protection against HIV/SIV infection: strategies and challenges for vaccine design. Int Rev Immunol (2009) 1.13
Anti-HIV IgA isotypes: differential virion capture and inhibition of transcytosis are linked to prevention of mucosal R5 SHIV transmission. AIDS (2013) 1.13
Inhibitory effect of HIV-specific neutralizing IgA on mucosal transmission of HIV in humanized mice. Blood (2012) 1.11
The Neonatal Fc receptor (FcRn) enhances human immunodeficiency virus type 1 (HIV-1) transcytosis across epithelial cells. PLoS Pathog (2013) 1.07
Secretory IgA: arresting microbial pathogens at epithelial borders. Immunol Invest (2010) 1.04
Postnatally-transmitted HIV-1 Envelope variants have similar neutralization-sensitivity and function to that of nontransmitted breast milk variants. Retrovirology (2013) 0.98
Which Antibody Functions are Important for an HIV Vaccine? Front Immunol (2014) 0.94
Anti-HIV-1 response elicited in rabbits by anti-idiotype monoclonal antibodies mimicking the CD4-binding site. PLoS One (2008) 0.85
HIV-1 replication in Langerhans and interstitial dendritic cells is inhibited by neutralizing and Fc-mediated inhibitory antibodies. J Virol (2010) 0.85
Anti-gp120 minibody gene transfer to female genital epithelial cells protects against HIV-1 virus challenge in vitro. PLoS One (2011) 0.84
Comparative Evaluation of HIV-1 Neutralization in External Secretions and Sera of HIV-1-Infected Women. Open AIDS J (2012) 0.82
Back to the future: covalent epitope-based HIV vaccine development. Expert Rev Vaccines (2010) 0.80
Simplifying the synthesis of SIgA: combination of dIgA and rhSC using affinity chromatography. Methods (2013) 0.78
Humoral immune responses to HIV in the mucosal secretions and sera of HIV-infected women. Am J Reprod Immunol (2014) 0.78
Novel Monoclonal Antibodies for Studies of Human and Rhesus Macaque Secretory Component and Human J-Chain. Monoclon Antib Immunodiagn Immunother (2016) 0.78
Neutralization of HIV by milk expressed antibody. J Acquir Immune Defic Syndr (2013) 0.76
Mother-to-Child HIV-1 Transmission Events Are Differentially Impacted by Breast Milk and Its Components from HIV-1-Infected Women. PLoS One (2015) 0.75
Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science (1994) 13.54
Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature (2005) 13.15
Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med (2000) 11.90
HIV vaccine design and the neutralizing antibody problem. Nat Immunol (2004) 9.48
Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol (2004) 8.99
Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol (2001) 8.64
Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med (2000) 7.48
Rapid complementation assays measuring replicative potential of human immunodeficiency virus type 1 envelope glycoprotein mutants. J Virol (1990) 6.54
Measurements of the true affinity constant in solution of antigen-antibody complexes by enzyme-linked immunosorbent assay. J Immunol Methods (1985) 6.11
Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med (2003) 5.71
Mucosal immunity and vaccines. Nat Med (2005) 5.44
Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science (2001) 5.39
Inhibiting sexual transmission of HIV-1 infection. Nat Rev Microbiol (2003) 5.29
HIV disease: fallout from a mucosal catastrophe? Nat Immunol (2006) 5.08
Parameters of human immunodeficiency virus infection of human cervical tissue and inhibition by vaginal virucides. J Virol (2000) 3.68
Antibody avidity determination by ELISA using thiocyanate elution. J Immunol Methods (1986) 3.07
Primary intestinal epithelial cells selectively transfer R5 HIV-1 to CCR5+ cells. Nat Med (2002) 3.04
Comparison of the oral, rectal, and vaginal immunization routes for induction of antibodies in rectal and genital tract secretions of women. Infect Immun (1997) 2.49
IgA subclasses in various secretions and in serum. Immunology (1982) 2.43
Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract. J Immunol (2004) 2.42
The function of immunoglobulin A in immunity. J Pathol (2006) 2.31
Secretory component: a new role in secretory IgA-mediated immune exclusion in vivo. Immunity (2002) 2.17
Infection of colonic epithelial cell lines by type 1 human immunodeficiency virus is associated with cell surface expression of galactosylceramide, a potential alternative gp120 receptor. Proc Natl Acad Sci U S A (1993) 1.96
High-level expression of a recombinant antibody from myeloma cells using a glutamine synthetase gene as an amplifiable selectable marker. Biotechnology (N Y) (1992) 1.92
Antibody-enhanced pneumococcal adherence requires IgA1 protease. Proc Natl Acad Sci U S A (2003) 1.81
Cell-free human immunodeficiency virus type 1 transcytosis through primary genital epithelial cells. J Virol (2006) 1.74
Modified wick method using Weck-Cel sponges for collection of human rectal secretions and analysis of mucosal HIV antibody. J Acquir Immune Defic Syndr (2000) 1.65
Characterization of human class-switched polymeric (immunoglobulin M [IgM] and IgA) anti-human immunodeficiency virus type 1 antibodies 2F5 and 2G12. J Virol (2003) 1.45
Neutralizing antibodies against HIV -- back in the major leagues? Curr Opin Immunol (2002) 1.44
Polymeric IgA is superior to monomeric IgA and IgG carrying the same variable domain in preventing Clostridium difficile toxin A damaging of T84 monolayers. J Immunol (2000) 1.34
Cervical and prostate primary epithelial cells are not productively infected but sequester human immunodeficiency virus type 1. J Infect Dis (2001) 1.33
Magnitude, duration, quality, and function of pneumococcal vaccine responses in elderly adults. J Infect Dis (1998) 1.26
Contribution of proteoglycans to human immunodeficiency virus type 1 brain invasion. J Virol (2004) 1.23
Conformational changes in env oligomer induced by an antibody dependent on the V3 loop base. AIDS (2003) 1.22
Detection of mucosal antibodies in HIV type 1-infected individuals. AIDS Res Hum Retroviruses (2002) 1.21
Role of J chain in secretory immunoglobulin formation. Scand J Immunol (2000) 1.17
The role of mucosal immunity in prevention of HIV transmission. Curr Mol Med (2003) 1.16
The J chain is essential for polymeric Ig receptor-mediated epithelial transport of IgA. J Immunol (2001) 1.13
Purification and characterization of chimeric human IgA1 and IgA2 expressed in COS and Chinese hamster ovary cells. J Immunol (1993) 1.07
Humoral recall responses in HIV infection. Levels, specificity, and affinity of antigen-specific IgG. J Immunol (1991) 1.04
Infection of vaginal and colonic epithelial cells by the human immunodeficiency virus type 1 is neutralized by antibodies raised against conserved epitopes in the envelope glycoprotein gp120. Proc Natl Acad Sci U S A (1994) 1.00
Comparative studies of transcytosis and assembly of secretory IgA in Madin-Darby canine kidney cells expressing human polymeric Ig receptor. J Immunol (1995) 0.97
Expression and functional activity of isotype and subclass switched human monoclonal antibody reactive with the base of the V3 loop of HIV-1 gp120. AIDS Res Hum Retroviruses (2003) 0.96
In vitro comparison of the antigen-binding and stability properties of the various molecular forms of IgA antibodies assembled and produced in CHO cells. Proc Natl Acad Sci U S A (1999) 0.93
Structural requirements for the interaction of human IgA with the human polymeric Ig receptor. J Immunol (2005) 0.92
Interferon-gamma induces polymeric immunoglobulin receptor mRNA in human intestinal epithelial cells by a protein synthesis dependent mechanism. Mol Immunol (1993) 0.90
Protection by intranasal immunization of a nef-deleted, nonpathogenic SHIV against intravaginal challenge with a heterologous pathogenic SHIV. Virology (2002) 0.86
Solid phase disruption of fluid phase equilibrium in affinity assays with ELISA. J Immunol Methods (1990) 0.86
Effect of polyanion-resistance on HIV-1 infection. Virology (2004) 0.84
Complete replication of hepatitis C virus in cell culture. Science (2005) 18.59
Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science (2009) 17.14
Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A (2005) 14.78
Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature (2007) 11.73
Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature (2011) 11.07
HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature (2002) 9.62
Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science (2011) 9.00
Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol (2004) 8.99
Fc receptor but not complement binding is important in antibody protection against HIV. Nature (2007) 7.96
Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science (2011) 7.92
The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120. J Virol (2002) 7.82
Printed covalent glycan array for ligand profiling of diverse glycan binding proteins. Proc Natl Acad Sci U S A (2004) 7.55
Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature (2011) 7.20
Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science (2003) 6.68
Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat Med (2009) 6.14
Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med (2007) 6.05
Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis (2008) 5.94
Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med (2009) 5.87
Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog (2009) 5.82
Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med (2003) 5.71
Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. J Virol (2003) 5.59
Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science (2013) 5.53
A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science (2011) 5.44
GP120: target for neutralizing HIV-1 antibodies. Annu Rev Immunol (2006) 5.28
Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature (2008) 5.24
Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N Engl J Med (2014) 4.91
Toward an AIDS vaccine. Science (2008) 4.83
Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J Virol (2006) 4.68
Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science (2013) 4.61
Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J Virol (2003) 4.49
A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog (2010) 4.47
Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions. Clin Infect Dis (2008) 4.46
The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat Rev Microbiol (2008) 4.45
Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J Virol (2007) 4.45
Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity (2005) 4.26
Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science (2009) 4.20
Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. Clin Infect Dis (2008) 3.91
Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature (2013) 3.90
HIV vaccine research: the way forward. Science (2008) 3.86
Rational HIV immunogen design to target specific germline B cell receptors. Science (2013) 3.55
A change in the conformation of prions accompanies the emergence of a new prion strain. Neuron (2002) 3.36
Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med (2008) 3.35
Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J Virol (2006) 3.34
Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc Natl Acad Sci U S A (2012) 3.30
A genetically humanized mouse model for hepatitis C virus infection. Nature (2011) 3.15
Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis (2009) 3.12
Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat Struct Mol Biol (2013) 3.11
Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. Proc Natl Acad Sci U S A (2002) 3.08
Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120. Cell (2003) 3.03
Clinical features and serum biomarkers in HIV immune reconstitution inflammatory syndrome after cryptococcal meningitis: a prospective cohort study. PLoS Med (2010) 2.94
Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1. Proc Natl Acad Sci U S A (2010) 2.77
Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16. J Virol (2010) 2.76
HIV vaccine design: insights from live attenuated SIV vaccines. Nat Immunol (2006) 2.72
Carbohydrate vaccines: developing sweet solutions to sticky situations? Nat Rev Drug Discov (2010) 2.69
Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans. PLoS Pathog (2013) 2.66
Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog (2007) 2.64
Macaques vaccinated with live-attenuated SIV control replication of heterologous virus. J Exp Med (2008) 2.59
Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens. Proc Natl Acad Sci U S A (2010) 2.51
Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12. Proc Natl Acad Sci U S A (2005) 2.50
The human nasal microbiota and Staphylococcus aureus carriage. PLoS One (2010) 2.50
Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr Opin Immunol (2010) 2.47
Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16. Nat Struct Mol Biol (2013) 2.42
Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc Natl Acad Sci U S A (2011) 2.39
Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies. J Virol (2003) 2.34
Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. J Virol (2011) 2.34
A dominant role for CD8+-T-lymphocyte selection in simian immunodeficiency virus sequence variation. J Virol (2004) 2.33
Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma. J Virol (2006) 2.33
Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. J Virol (2002) 2.31
Redox-triggered infection by disulfide-shackled human immunodeficiency virus type 1 pseudovirions. J Virol (2003) 2.31
Measuring prions causing bovine spongiform encephalopathy or chronic wasting disease by immunoassays and transgenic mice. Nat Biotechnol (2002) 2.24
Paucity of initial cerebrospinal fluid inflammation in cryptococcal meningitis is associated with subsequent immune reconstitution inflammatory syndrome. J Infect Dis (2010) 2.19
Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. Immunity (2013) 2.17
Secretory component: a new role in secretory IgA-mediated immune exclusion in vivo. Immunity (2002) 2.17
Contrasting IgG structures reveal extreme asymmetry and flexibility. J Mol Biol (2002) 2.10
Targeting the carbohydrates on HIV-1: Interaction of oligomannose dendrons with human monoclonal antibody 2G12 and DC-SIGN. Proc Natl Acad Sci U S A (2008) 2.09
Hepatitis C virus E2 envelope glycoprotein core structure. Science (2013) 2.06
Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Proc Natl Acad Sci U S A (2012) 2.05
Difficulties in eliciting broadly neutralizing anti-HIV antibodies are not explained by cardiolipin autoreactivity. AIDS (2007) 2.03
The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5. J Virol (2004) 2.02
Crystal structure of the broadly cross-reactive HIV-1-neutralizing Fab X5 and fine mapping of its epitope. Biochemistry (2004) 2.01
Phase variable desialylation of host proteins that bind to Streptococcus pneumoniae in vivo and protect the airway. Mol Microbiol (2004) 1.97
The glycan shield of HIV is predominantly oligomannose independently of production system or viral clade. PLoS One (2011) 1.95
Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins. J Virol (2002) 1.93
Human antibody-Fc receptor interactions illuminated by crystal structures. Nat Rev Immunol (2004) 1.91
Structural basis of enhanced binding of extended and helically constrained peptide epitopes of the broadly neutralizing HIV-1 antibody 4E10. J Mol Biol (2006) 1.90
Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs. PLoS Pathog (2013) 1.85
Molecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120. J Virol (2003) 1.84
Antibody-enhanced pneumococcal adherence requires IgA1 protease. Proc Natl Acad Sci U S A (2003) 1.81
Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody. J Virol (2004) 1.80
Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design. J Virol (2003) 1.78
Differential induction of mucosal and systemic antibody responses in women after nasal, rectal, or vaginal immunization: influence of the menstrual cycle. J Immunol (2002) 1.76